Get real, no such thing as Climate change, or climate destruction, or what ever term you progress left wing nuts use....Only climate change taking place is between your liberals minds.
Buyout stock? With a $140 B market cap. Are u serious? Who in the hell could afford to buy them out?
July 24, 2014 6:40 AM EDT
BMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following ...
Gilead price target raised to $109 from $99 at Leerink
Leerink raised its price target for Gilead shares to $109 citing improved gross margins and tax rate following the company's Q2 results. The firm keeps an Outperform rating on the stock.
Analyst already have factor in these number, management has finally come around & agree with the analyst numbers. The big surprise were the earnings numbers & the 60% profit margins.
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $141.00 (from $130.00) given his bullish view on Sovaldi.
Somaiya commented, "We raise our TP on GILD to $141, from $130, on strength of prescription data for Sovaldi and our assumptions for peak sales of $22bn (up from $16bn) based on launch of new two-drug and three-drug HCV combos in 2017 and 2018, respectively. We expect Phase I/II data by year-end to confirm their ability to maintain cure rates above 90%, while reducing treatment duration to six weeks. Our revised model strengthens our view that GILD is the most attractively priced large-cap growth stock in the healthcare industry, with a 2015E P/E of 11.2x. With free cash flow expected to reach ~$8.8bn in 2014 and ~$13bn in 2015, we believe GILD will not only continue to aggressively buy back shares, but also introduce a dividend in 2015."
The firm maintained FY14E EPS at $7.5; FY15E EPS at $8.14.
“I would expect the stock to trade [roughly] flattish on the print,” ISI Group analyst Mark Schoenebaum said in a quick note to clients. He notes that Gilead’s results soundly beat estimates from sell-side analysts, but were in line with buy-side watchers of the company.
There also may be some skittishness over the success of Sovaldi, Gilead’s blockbuster Hepatitis C drug that has generated an onslaught of criticism over it’s $1,000-a-day price tag. Insurers are calling for Gilead to bring down Sovaldi’s price, saying it’s unsustainable while a number of rivals are waiting in the wings with their own Hepatitis C alternatives.
What may be unsustainable for Gilead is how much Sovaldi contributes to sales, accounting for half the Foster City, Calif.-based company’s revenue. Gilead also reported an other-worldly net margin of more than 55% for the quarter. Using adjusted income figures, that margin exceeds 60%.
That's funny, because I just cover my short position for $12,000. Yell baby learn to trade. Traders make money, investors get screw.
Yingli gains following 32MW Japanese deal
Yingli (YGE +3.3%) is supplying 32MW of modules in 2015 for a "large-scale" solar project in Okayama, Japan.
The company mentioned in its Q1 report it's seeing "exceptional demand" in Japan (shipments up over 50% Q/Q). That, along with U.S./European growth, is helping offset Chinese softness.
To bad JKS has very little business out side of China
Do u really want to be long this pos when earnings come out? You know after they miss big on earnings again , the MM will drop this $10. Join in the fun & start a short position. See u bag holders at $3... Lol
They need the money badly. Short away boys, see u at $3
Jaso is getting ready to do a massive $250 million share holder dilution, that's why JASO not going up. Just like JKS did 6 months ago. It's the only way solar company's can make money, is to screw it's share holders. LOl .. Short away boys, this pos is going down for the count.
30 year in business, $6 billion in sales, & operates in 91 countries. Keep drinking the cool aide FOOL!
Whirlpool misses by $0.29, misses on revenue
Whirlpool (NYSE:WHR): Q2 EPS of $2.62 misses by $0.29.
Revenue of $4.68B (-1.5% Y/Y) misses by $170M.
Whirlpool Corp. sees FY2014 EPS of $11.50-$12.00, versus the consensus of $12.